AREV Life Sciences Global Corp.
AREVF
$0.01
$0.000.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | 5.30K | 23.00K | 31.00K | 37.80K | 145.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.30K | 23.00K | 31.00K | 37.80K | 145.20K |
| Cost of Revenue | 14.70K | 14.70K | 14.70K | 14.70K | 12.40K |
| Gross Profit | -9.40K | 8.30K | 16.30K | 23.10K | 132.70K |
| SG&A Expenses | 58.40K | 212.90K | 693.10K | 952.60K | 1.31M |
| Depreciation & Amortization | 52.00K | 66.60K | 82.50K | 96.70K | 103.70K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 150.20K | 323.30K | 842.30K | 1.13M | 1.48M |
| Operating Income | -144.90K | -300.30K | -811.30K | -1.09M | -1.33M |
| Income Before Tax | -178.10K | -340.90K | -856.50K | -1.13M | -794.70K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.18 | -0.34 | -0.86 | -1.13 | -0.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -178.10K | -340.90K | -856.50K | -1.13M | -794.70K |
| EBIT | -144.90K | -300.30K | -811.30K | -1.09M | -1.33M |
| EBITDA | -101.60K | -242.40K | -737.60K | -1.00M | -1.24M |
| EPS Basic | -0.01 | -0.01 | -0.03 | -0.04 | 0.02 |
| Normalized Basic EPS | 0.00 | -0.01 | -0.02 | -0.02 | -0.04 |
| EPS Diluted | -0.01 | -0.01 | -0.03 | -0.04 | 0.02 |
| Normalized Diluted EPS | 0.00 | -0.01 | -0.02 | -0.02 | -0.04 |
| Average Basic Shares Outstanding | 126.75M | 125.56M | 124.03M | 120.36M | 95.17M |
| Average Diluted Shares Outstanding | 126.75M | 125.56M | 124.03M | 120.36M | 95.17M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |